Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Consolidated Net Income (2016 - 2025)

International Stem Cell (ISCO) has disclosed Consolidated Net Income for 16 consecutive years, with $91000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Consolidated Net Income fell 20.18% to $91000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was -$115000.0, a 83.16% increase, with the full-year FY2024 number at -$213000.0, up 73.44% from a year prior.
  • Consolidated Net Income was $91000.0 for Q2 2025 at International Stem Cell, up from -$218000.0 in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $114000.0 in Q2 2024 to a low of -$641000.0 in Q3 2021.
  • A 5-year average of -$194833.3 and a median of -$155000.0 in 2023 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: tumbled 8850.0% in 2023, then surged 163.69% in 2024.
  • International Stem Cell's Consolidated Net Income stood at -$362000.0 in 2021, then soared by 107.73% to $28000.0 in 2022, then tumbled by 1735.71% to -$458000.0 in 2023, then skyrocketed by 102.62% to $12000.0 in 2024, then skyrocketed by 658.33% to $91000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Consolidated Net Income are $91000.0 (Q2 2025), -$218000.0 (Q1 2025), and $12000.0 (Q4 2024).